What this medicine is commonly used for
Procurement teams reference Sotorasib when aligning formulary decisions, documenting a named patient request, or preparing a quotation for a destination country where the product is not routinely stocked.
Informational only. Treatment decisions belong to qualified clinicians and to local labeling.
Shortage and sourcing context
Requests usually follow molecular testing, so timelines matter: the patient is identified before a supply route exists in that country. Reimbursement status and authorization differ widely between markets, which is what most inquiries turn on.
How it is presented
Examples of presentations referenced for this medicine. Actual market presentations vary by country and registration, so check the pack in front of you.
- Tablet
Who typically asks us about this medicine
- Patients and families who cannot fill a prescription locally
- Hospital pharmacies managing formulary access during a shortage
- Clinics with defined treatment pathways and continuity of care
- Procurement teams coordinating licensed cross-border sourcing
Full reference text(expand)
Sotorasib (Lumakras, Lumykras): An oral KRAS G12C inhibitor for previously treated non-small cell lung cancer carrying that mutation. Procurement-oriented reference for licensed buyers - not medical advice, and availability depends on region and authorization.
Procurement context
Procurement teams reference Sotorasib when aligning formulary decisions, documenting a named patient request, or preparing a quotation for a destination country where the product is not routinely stocked.
What makes it hard to source
Requests usually follow molecular testing, so timelines matter: the patient is identified before a supply route exists in that country. Reimbursement status and authorization differ widely between markets, which is what most inquiries turn on.